Biotechnology company and drug delivery platform innovator
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional
significant findings of TurboCBD(TM), the company’s proprietary,
DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon
completion of further data analyses from its 2018 randomized,
placebo-controlled, double-blinded European human clinical study. According to
the update, a single 90mg dose of TurboCBD as compared to the same dose of
generic CBD provided evidence of lower blood pressure, higher blood flow to the
brain, faster delivery onset and larger quantities of CBD into the bloodstream.
The study revealed key metabolic and hemodynamic performance findings linked to
bioavailability enhancements. “The findings that Lexaria’s DehydraTECH(TM)
technology can enable superior cannabinoid delivery are unique in this
healthy-human clinical trial. However, the findings that the technology can
proffer a positive influence on blood pressure and perfusion to the brain are
truly remarkable,” Principal Investigator and Co-Director of the Centre for
Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada Professor
Philip Ainslie, Ph.D. stated in the news release. “The potential benefits of
this approach, but over the acute and more chronic time periods, in more
middle-aged or elderly populations should now be prioritized. Establishing the
impact of CBD delivery on the health of the circulatory systems, including the
brain, could have major implications for the adjunct treatment of high blood
pressure and some neurological diseases.”
To view the full press release, visit http://ibn.fm/cJ6ce
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its DehydraTECH(TM)
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important
taste-masking benefits, for orally administered bioactive molecules including
cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),nicotine
and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment